<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <!--Page title-->
    <title>Emma Torrini</title>
    <!--Link to CSS file-->
    <link rel="stylesheet" href="./psi-poster.css">
    <!--Link to Poppins font-->
    <link href='https://fonts.googleapis.com/css?family=Poppins' rel='stylesheet'>
    <!--Link to have FA4 icons-->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
</head>
<body>

    <!--NAVIGATION BAR-->
    <header>
        <li id="name"><a href="#headshot" onclick=hideSidebar()><h2><strong>Emma Torrini</strong></h2></a></li>
        <nav>
            <!--Vertical navbar (smaller screens)-->
            <ul class="side-bar">
                <li onclick=hideSidebar()><a href="javascript:void(0)"><i class="fa fa-remove"></i></a></li>
                <li><a href="#experience" onclick=hideSidebar()>Experience</a></li>
                <li><a href="#education" onclick=hideSidebar()>Education</a></li>
                <li><a href="#publications" onclick=hideSidebar()>Publications</a></li>
                <li><a href="#projects" onclick=hideSidebar()>Projects</a></li>
                <li><a href="#hobbies" onclick=hideSidebar()>Hobbies</a></li>
                <li><a href="#cv" onclick=hideSidebar()>CV</a></li>
                <li><a href="#contact" onclick=hideSidebar()>Contact</a></li>
            </ul>
            <!--Horizontal navbar (wider screens)-->
            <ul id="horizontal-bar">
                <li class="hide-on-mobile"><a href="#experience">Experience</a></li>
                <li class="hide-on-mobile"><a href="#education">Education</a></li>
                <li class="hide-on-mobile"><a href="#publications">Publications</a></li>
                <li class="hide-on-mobile"><a href="#projects">Projects</a></li>
                <li class="hide-on-mobile"><a href="#hobbies">Hobbies</a></li>
                <li class="hide-on-mobile"><a href="#cv">CV</a></li>
                <li class="hide-on-mobile"><a href="#contact">Contact</a></li>
                <li class="menu-button" onclick=showSidebar()><a href="javascript:void(0)"><i class="fa fa-navicon"></i></a></li>
            </ul>
        </nav>
    </header>

    <div class="text">
        <h3>A Bayesian approach to principal stratification for exponentially distributed time-to-event endpoints</h3>
        <p class="authors">
            Emma Torrini, Benjamin Lang, Fabrizia Mealli, Christian Stock <br>
            <em>PSI 2023 conference in London (UK), June 2023</em>
        </p>
        <img class="image"
             src="poster_psi_A0_230516_DEF.jpg" alt="PSI 2023 poster image">
        <p>
            <strong>Abstract</strong> <br> <br>

            Principal stratification has been proposed as one approach to deal with intercurrent 
            events in the ICH E9 (R1) addendum (2019). However, so far, limited experience exists
            with principal stratification in the context of clinical trials, especially with respect to
            situations where interest is in a time-to-event endpoint. <br> <br>
            
            Our work is motivated by questions arising in the development of biological drugs in rare
            immunological diseases, where patients under the investigational treatment may have an
            immune response that leads to the development of antidrug antibodies (ADAs). If ADAs
            occur, they can have a (negative) impact on the efficacy of the drug. It is thus commonly
            an important secondary objective in phase II/III trials to explore the efficacy of the drug in
            patients who develop ADAs. More precisely, it is of interest to estimate the effect of the
            drug in the principal stratum of patients who would develop ADAs if given treatment. <br> <br>

            We propose a basic Bayesian principal stratification approach for exponentially
            distributed time-to-event endpoints that is applicable to the described setting. It allows
            consideration of predictors of ADA development. We focus on the estimation of hazard
            ratios and restricted mean survival times using Markov chain Monte Carlo methods. Our
            simulation results show that the methodology can validly estimate the parameters of
            interest. Given the typical sizes of phase II/III trials, the Bayesian approach may be
            particularly advantageous since it allows use of prior information. <br> <br>

            Overall, this work lays theoretical and practical foundations for desirable extensions,
            including the use of flexible time-to-event distributions. <br> <br>
            
            <strong>Additional information</strong> <br> <br>

            This poster was one of four to receive the award for best conference poster.
        </p>
    </div>
    
    <script>
        function showSidebar() {
            const sidebar = document.querySelector('.side-bar')
            sidebar.style.display = 'flex'
        }
        function hideSidebar() {
            const sidebar = document.querySelector('.side-bar')
            sidebar.style.display = 'none'
        }
    </script>
</body>
</html>